Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

被引:419
|
作者
Kasahara, A
Hayashi, N
Mochizuki, K
Takayanagi, M
Yoshioka, K
Kakumu, S
Iijima, A
Urushihara, A
Kiyosawa, K
Okuda, M
Hino, K
Okita, K
机构
[1] Osaka Univ, Sch Med, Dept Med 1, Suita, Osaka 5650871, Japan
[2] Nagoya Univ, Sch Med, Dept Med 3, Nagoya, Aichi 466, Japan
[3] Shinshu Univ, Sch Med, Dept Med 2, Matsumoto, Nagano 390, Japan
[4] Yamaguchi Univ, Sch Med, Dept Med 1, Ube, Yamaguchi 755, Japan
关键词
D O I
10.1002/hep.510270529
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405, Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P = .0009), The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders mere estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P = .14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P = .008), Patients greater than or equal to 55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P = .006). The risk of HCC development in men was 4.35 times higher than the risk in women (P = .02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.
引用
收藏
页码:1394 / 1402
页数:9
相关论文
共 50 条
  • [31] Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C
    Yutaka Yamanaka
    Katsuya Shiraki
    Kazumi Miyashita
    Tomoko Inoue
    Tomoyuki Kawakita
    Yumi Yamaguchi
    Yukiko Saitou
    Norihiko Yamamoto
    Takeshi Nakano
    Atsuhiro Nakatsuka
    Koichiro Yamakado
    Kan Takeda
    World Journal of Gastroenterology, 2005, (14) : 2174 - 2178
  • [32] Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C
    Yamanaka, Yutaka
    Shiraki, Katsuya
    Miyashita, Kazumi
    Inoue, Tomoko
    Kawakita, Tomoyuki
    Yamaguchi, Yumi
    Saitou, Yukiko
    Yamamoto, Norihiko
    Nakano, Takeshi
    Nakatsuka, Atsuhiro
    Yamakado, Koichiro
    Takeda, Kan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (14) : 2174 - 2178
  • [33] Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C
    Carlos Gavilan, Juan
    Ojeda, Guillermo
    Arnedo, Rocio
    Puerta, Susana
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (08) : 846 - 851
  • [34] HEPATOCELLULAR CARCINOMA INCIDENCE IN CHRONIC HEPATITIS C PATIENTS ACCORDING TO ANTIVIRAL TREATMENT STATUS
    Purevsambuu, T.
    Bota, S.
    Hucke, F.
    Hofer, H.
    Ferenci, P.
    Sieghart, W.
    Peck-Radosavljevic, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S446 - S447
  • [35] Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy
    Shindo, M
    Ken, A
    Okuno, T
    CANCER, 1999, 85 (09) : 1943 - 1950
  • [36] Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
    Imai, Y
    Kawata, S
    Tamura, S
    Yabuuchi, I
    Noda, S
    Inada, M
    Maeda, Y
    Shirai, Y
    Fukuzaki, T
    Kaji, I
    Ishikawa, H
    Matsuda, Y
    Nishikawa, M
    Seki, K
    Matsuzawa, Y
    ANNALS OF INTERNAL MEDICINE, 1998, 129 (02) : 94 - 99
  • [37] Does interferon treatment reduce hepatocellular carcinoma incidence in HBeAg positive chronic hepatitis B patients?
    Hosaka, Tetsuya
    Suzuki, Fumitaka
    Kobayashi, Masahiro
    Fukushima, Taito
    Kawamura, Yusuke
    Sezaki, Hitomi
    Akuta, Norio
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kobayashi, Mariko
    Kumada, Hiromitsu
    HEPATOLOGY, 2014, 60 : 1120A - 1120A
  • [38] Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B
    Goh, Myung Ji
    Kang, Wonseok
    Kim, Kwang Min
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (01) : 70 - 77
  • [39] Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy
    Iwasaki, Y
    Takaguchi, K
    Ikeda, H
    Makino, Y
    Araki, Y
    Ando, M
    Kobashi, H
    Kobatake, T
    Tanaka, R
    Tomita, M
    Senoh, T
    Kawaguchi, M
    Shimoe, T
    Manabe, K
    Kita, K
    Shimamura, J
    Sakaguchi, K
    Shiratori, Y
    LIVER INTERNATIONAL, 2004, 24 (06) : 603 - 610
  • [40] INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIRECT-ACTING ANTIVIRALS (DAAS).
    Leal, Cassia
    Teixeira, Rosangela
    Perez, Renata M.
    Theodoro, Carmem Ferguson
    Guarana, Thais
    Strogoff De Mattos, Jorge Paulo
    Noronha, Tatiana Guimaraes
    Aparecida Pinto, Paulo De Tarso
    Oliveira, Solange Artimos
    HEPATOLOGY, 2023, 77 (05) : E149 - E150